{"id":125736,"date":"2024-11-14T12:39:51","date_gmt":"2024-11-14T05:39:51","guid":{"rendered":"https:\/\/hotvideos24.online\/?p=125736"},"modified":"2024-11-14T12:39:51","modified_gmt":"2024-11-14T05:39:51","slug":"schizophrenia-risks-tied-to-psychedelic-use","status":"publish","type":"post","link":"https:\/\/hotvideos24.online\/?p=125736","title":{"rendered":"Schizophrenia Risks Tied to Psychedelic Use"},"content":{"rendered":"<p> <script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3711241968723425\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-format=\"fluid\"\r\n     data-ad-layout-key=\"-fb+5w+4e-db+86\"\r\n     data-ad-client=\"ca-pub-3711241968723425\"\r\n     data-ad-slot=\"7910942971\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><br \/>\n<\/p>\n<div>\n<p><strong>Summary: <\/strong>A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to the general population. Even after accounting for other mental health disorders and substance use, individuals faced a 3.5-fold higher risk.<\/p>\n<p>Rates of hallucinogen-related ED visits surged by 86% between 2013 and 2021, highlighting the growing popularity of psychedelics. While the findings don\u2019t prove causation, they underscore potential risks, especially for individuals predisposed to psychosis. Researchers urge caution with hallucinogen use outside controlled therapeutic settings.<\/p>\n<p><strong>Key Facts<\/strong>:<\/p>\n<ul class=\"wp-block-list\">\n<li>Individuals with hallucinogen-related ED visits face a 21-fold higher schizophrenia risk.<\/li>\n<li>Rates of ED visits involving hallucinogens rose 86% from 2013 to 2021.<\/li>\n<li>Schizophrenia risk remains 3.5 times higher even when adjusting for other factors.<\/li>\n<\/ul>\n<p><strong>Source: <\/strong>ICES<\/p>\n<p><strong>Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, according to a new study from researchers at ICES, The Ottawa Hospital, University of Ottawa\u2019s Department of Family Medicine, and Bruy\u00e8re Health Research Institute.\u00a0<\/strong><\/p>\n<p>These findings come as psychedelics, a type of hallucinogen, grow in popularity across North America in both recreational and therapeutic contexts. Hallucinogens include drugs such as psilocybin, LSD, DMT (Ayahuasca), and MDMA (Ecstasy).\u00a0<\/p>\n<figure class=\"wp-block-image size-full\"><picture fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-106147\"><source type=\"image\/webp\" srcset=\"https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence.jpg.webp 1200w, https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence-300x200.jpg.webp 300w, https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence-770x513.jpg.webp 770w, https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence-1155x770.jpg.webp 1155w, https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence-370x247.jpg.webp 370w, https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence-293x195.jpg.webp 293w, https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence-150x100.jpg.webp 150w\" sizes=\"(max-width: 1200px) 100vw, 1200px\"\/><img fetchpriority=\"high\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence.jpg\" alt=\"This shows an outline of a person sitting in a chair surrounded by swirly lines.\" srcset=\"https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence.jpg 1200w, https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence-300x200.jpg 300w, https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence-770x513.jpg 770w, https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence-1155x770.jpg 1155w, https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence-370x247.jpg 370w, https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence-293x195.jpg 293w, https:\/\/neurosciencenews.com\/files\/2024\/11\/psychedelics-schizophrenia-neurosicence-150x100.jpg 150w\" sizes=\"(max-width: 1200px) 100vw, 1200px\"\/> <\/picture><figcaption class=\"wp-element-caption\">Even after considering an individual\u2019s co-occurring substance use and mental health disorders, the study found a 3.5-fold increased risk of schizophrenia. Credit: Neuroscience News<\/figcaption><\/figure>\n<p>The study, which followed over 9.2 million individuals in Ontario, Canada, found that those with a hallucinogen-related emergency department (ED) visit had a 21-fold increased risk of developing schizophrenia compared to the general population.\u00a0<\/p>\n<p>Even after considering an individual\u2019s co-occurring substance use and mental health disorders, the study found a 3.5-fold increased risk of schizophrenia.\u00a0<\/p>\n<p>\u201cOur findings underscore a concerning link between hallucinogen use that requires care in the emergency room and increased risk of schizophrenia,\u201d says Dr. Daniel Myran, a Canada Research Chair in Social Accountability at the University of Ottawa, ICES Adjunct Scientist, Investigator at the Bruy\u00e8re Health Research Institute, and Clinician Investigator at The Ottawa Hospital.\u00a0\u00a0<\/p>\n<p>\u201cWhile there is enormous enthusiasm for psychedelic-assisted therapy as a new mental health treatment, we need to remember how early and limited the data remains for both the benefits and the risks,\u201d adds Myran.\u00a0<\/p>\n<p>Published in the journal\u00a0<em>JAMA Psychiatry<\/em>, researchers analysed health data for people aged 14 to 65 years old living in Ontario from 2008 to 2021.\u00a0\u00a0<\/p>\n<p>The authors looked at changes in the number of ED visits involving hallucinogens over time, along with the risk of being diagnosed with schizophrenia after such visits.\u00a0<\/p>\n<p><strong>Key findings:\u00a0<\/strong><\/p>\n<ul class=\"wp-block-list\">\n<li>While annual rates of ED visits involving hallucinogens were stable between 2008 and 2012, they increased by 86% between 2013 and 2021.\u00a0<\/li>\n<li>Within three years of an ED visit involving hallucinogens, 4% of individuals were diagnosed with schizophrenia, compared to 0.15% for members of the general population followed for the same period\u2014a risk 21 times higher.\u00a0\u00a0<\/li>\n<li>Individuals with ED visits involving hallucinogens were at 4.7 and 1.5 times higher risk of schizophrenia respectively compared to individuals with ED visits involving alcohol and cannabis.\u00a0\u00a0<\/li>\n<\/ul>\n<p>The authors emphasize that their findings do not establish a causal link between hallucinogen use and schizophrenia and that much more information is needed about risks associated with different types and use patterns of hallucinogens.<\/p>\n<p>However, the study highlights risks associated with hallucinogen use that requires ED care and potentially in individuals with underlying susceptibility to psychosis or schizophrenia.<\/p>\n<p>The authors also emphasize the importance of further studies and public health measures to better understand and mitigate these risks.\u00a0<\/p>\n<p>\u201cClinical trials of psychedelic-assisted psychotherapy have safeguards, such as excluding individuals with a personal or family history of schizophrenia and close monitoring while participants use hallucinogens.<\/p>\n<p>\u201cOur findings provide a timely caution about potential risks of hallucinogen use outside of trial settings,\u201d says Myran.\u00a0\u00a0<\/p>\n<p>\u201cIt is also important that we are able to identify those at risk of developing serious adverse events from psychedelics requiring emergency care, so that future trials can screen for baseline risk of complications of psychedelic use and inform safe recruitment practice,\u201d says Dr. Marco Solmi, Director of Research at uOttawa Psychiatry Department and Medical Director of the On Track Early Intervention Service for psychosis in Ottawa.\u00a0<\/p>\n<h2 class=\"wp-block-heading\">About this psychedelics and schizophrenia research news<\/h2>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Author: <\/strong><a href=\"http:\/\/neurosciencenews.com\/cdn-cgi\/l\/email-protection#b5d8c5c7d4c1c1f5dcd6d0c69bdadb9bd6d4\" target=\"_blank\" rel=\"noreferrer noopener\">Misty Pratt<\/a><br \/><strong>Source: <\/strong><a href=\"https:\/\/ices.on.ca\" target=\"_blank\" rel=\"noreferrer noopener\">ICES<\/a><br \/><strong>Contact: <\/strong>Misty Pratt \u2013 ICES<br \/><strong>Image: <\/strong>The image is credited to Neuroscience News<\/p>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Original Research: <\/strong>Closed access.<br \/>\u201c<a href=\"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/article-abstract\/2825649\" target=\"_blank\" rel=\"noreferrer noopener\">Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder<\/a>\u201d by Daniel Myran et al. <em>JAMA Psychiatry<\/em><\/p>\n<hr class=\"wp-block-separator has-text-color has-pale-cyan-blue-color has-alpha-channel-opacity has-pale-cyan-blue-background-color has-background\"\/>\n<p><strong>Abstract<\/strong><\/p>\n<p><strong>Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder<\/strong><\/p>\n<p><strong>Importance<\/strong>\u00a0\u00a0<\/p>\n<p>Interest in and use of hallucinogens has been increasing rapidly. While a frequently raised concern is that hallucinogens may be associated with an increased risk of psychosis, there are limited data on this association.<\/p>\n<p><strong>Objectives<\/strong>\u00a0\u00a0<\/p>\n<p>To examine whether individuals with an emergency department (ED) visit involving hallucinogen use have an increased risk of developing a schizophrenia spectrum disorder (SSD).<\/p>\n<p><strong>Design, Settings, and Participants<\/strong>\u00a0\u00a0<\/p>\n<p>This population-based, retrospective cohort study (January 2008 to December 2021) included all individuals aged 14 to 65 years in Ontario, Canada, with no history of psychosis (SSD or substance induced). Data were analyzed from May to August 2024.<\/p>\n<p><strong>Exposure<\/strong>\u00a0\u00a0<\/p>\n<p>An incident ED visit involving hallucinogen use.<\/p>\n<p><strong>Main Outcomes and Measures<\/strong>\u00a0\u00a0<\/p>\n<p>Diagnosis of SSD using a medical record\u2013validated algorithm. Associations between ED visits involving hallucinogens and SSD were estimated using cause-specific adjusted hazard models. Individuals with an incident ED visit involving hallucinogens were compared with members of the general population (primary analysis) or individuals with ED visits involving alcohol or cannabis (secondary analysis).<\/p>\n<p><strong>Results<\/strong>\u00a0\u00a0<\/p>\n<p>The study included 9\u202f244\u202f292 individuals (mean [SD] age, 40.4 [14.7] years; 50.2% female) without a history of psychosis, with a median follow-up of 5.1 years (IQR, 2.3-8.6 years); 5217 (0.1%) had an incident ED visit involving hallucinogen use.<\/p>\n<p>Annual rates of incident ED visits involving hallucinogens were stable between 2008 and 2012 and then increased by 86.4% between 2013 and 2021 (3.4 vs 6.4 per 100\u202f000 individuals).<\/p>\n<p>Individuals with ED visits involving hallucinogens had a greater risk of being diagnosed with an SSD within 3 years compared with the general population (age- and sex-adjusted hazard ratio [HR], 21.32 [95% CI, 18.58-24.47]; absolute proportion with SSD at 3 years, 208 of 5217 with hallucinogen use [3.99%] vs 13 639 of 9 239 075 in the general population [0.15%]).<\/p>\n<p>After adjustment for comorbid substance use and mental health conditions, individuals with hallucinogen ED visits had a greater risk of SSD compared with the general population (HR, 3.53; 95% CI, 3.05-4.09). Emergency department visits involving hallucinogens were associated with an increased risk of SSD within 3 years compared with ED visits involving alcohol (HR, 4.66; 95% CI, 3.82-5.68) and cannabis (HR, 1.47; 95% CI, 1.21-1.80) in the fully adjusted model.<\/p>\n<p><strong>Conclusions and Relevance<\/strong>\u00a0\u00a0<\/p>\n<p>In this cohort study, individuals with an ED visit involving hallucinogen use had a greater risk of developing an SSD compared with both the general population and with individuals with ED visits for other types of substances. These findings have important clinical and policy implications given the increasing use of hallucinogens and associated ED visits.<\/p>\n<p> <!-- Form created by Optin Forms plugin by WPKube: create beautiful optin forms with ease! --> <!-- https:\/\/wpkube.com\/ --><!--optinforms-form5-container--> <!-- \/ Optin Forms --> <\/div>\n<p><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3711241968723425\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-format=\"fluid\"\r\n     data-ad-layout-key=\"-fb+5w+4e-db+86\"\r\n     data-ad-client=\"ca-pub-3711241968723425\"\r\n     data-ad-slot=\"7910942971\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><br \/>\n<br \/><div data-type=\"_mgwidget\" data-widget-id=\"1660802\">\r\n<\/div>\r\n<script>(function(w,q){w[q]=w[q]||[];w[q].push([\"_mgc.load\"])})(window,\"_mgq\");\r\n<\/script>\r\n<br \/>\n<br \/><a href=\"https:\/\/neurosciencenews.com\/schizophrenia-psychedelics-psychology-28040\/\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Summary: A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to the general population. Even after accounting for other mental health disorders and &hellip; <a href=\"https:\/\/hotvideos24.online\/?p=125736\" class=\"more-link\">Read More<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-125736","post","type-post","status-publish","format-standard","hentry","category-health","entry"],"_links":{"self":[{"href":"https:\/\/hotvideos24.online\/index.php?rest_route=\/wp\/v2\/posts\/125736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hotvideos24.online\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hotvideos24.online\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hotvideos24.online\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/hotvideos24.online\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=125736"}],"version-history":[{"count":0,"href":"https:\/\/hotvideos24.online\/index.php?rest_route=\/wp\/v2\/posts\/125736\/revisions"}],"wp:attachment":[{"href":"https:\/\/hotvideos24.online\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=125736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hotvideos24.online\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=125736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hotvideos24.online\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=125736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}